Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H32O4S |
Molecular Weight | 416.573 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]4([H])[C@@]2([H])[C@@H](CC5=CC(=O)CC[C@]45C)SC(C)=O
InChI
InChIKey=LXMSZDCAJNLERA-ZHYRCANASA-N
InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
Molecular Formula | C24H32O4S |
Molecular Weight | 416.573 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:56:14 UTC 2023
by
admin
on
Sat Dec 16 16:56:14 UTC 2023
|
Record UNII |
27O7W4T232
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ESSENTIAL MEDICINES LIST |
16
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
SPIRONOLACTONE CEVA [AUTHORIZED]
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
NDF-RT |
N0000011310
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
FDA ORPHAN DRUG |
430614
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
IARC | Spironolactone | ||
|
LIVERTOX |
NBK547921
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
NCI_THESAURUS |
C49186
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
WHO-ATC |
C03DA01
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
NDF-RT |
N0000175557
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
CARDALIS (AUTHORISED)
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
||
|
WHO-VATC |
QC03DA01
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2475
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
27O7W4T232
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
DTXSID6034186
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
1619006
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
52-01-7
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
DB00421
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
SPIRONOLACTONE
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
Spironolactone
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
100000092408
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
C840
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
5833
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
3184
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
SUB127260
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
ALTERNATIVE | |||
|
987
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
D013148
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
9241
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
SPIRONOLACTONE
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | Description: A light yellowish white to light yellowish brown powder; odourless or with a faint characteristic odour. Solubility: Practically insoluble in water; soluble in ethanol (~750 g/l) TS. Category: Diuretic. Storage: Spironolactone should be kept in a well-closed container, protected from light. Additional information: Spironolactone may show preliminary melting at about 135?C, followed by resolidification. Definition: Spironolactone contains not less than 97.0% and not more than 101.5% of C24H32O4S, calculated with reference to the dried substance. | ||
|
SUB10631MIG
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
CHEMBL1393
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
2875
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
150399
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
200-133-6
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
27O7W4T232
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | |||
|
m10157
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | Merck Index | ||
|
9997
Created by
admin on Sat Dec 16 16:56:16 UTC 2023 , Edited by admin on Sat Dec 16 16:56:16 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
TARGET->PARTIAL ANTAGONIST |
BINDING
|
||
|
TARGET -> INHIBITOR |
Is a prodrug that Inhibits through active metabolites.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG | |||
|
METABOLITE ACTIVE -> PRODRUG |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PRODRUG |
The pharmacological activity of spironolactone metabolites in man is not known. However, in the adrenalectomized rat the antimineralocorticoid activities of the metabolites C, TMS, and HTMS, relative to spironolactone, were 1.10, 1.28, and 0.32, respectively.
|
||
|
METABOLITE ACTIVE -> PRODRUG |
Has in vitro activity
|
||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
correction factor: for the calculation of content, multiply the peak area of impurity F by 2.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||